CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations

Oncogene

Volumn 24, Issue 24, 2005, Pages 3987-3994

  Hesson, Luke B ^a   Wilson, Robin ^a   Morton, Dion ^a   Adams, Clare ^a   Walker, Mike ^a   Maher, Eamonn R ^a   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Colorectal cancer; Epigenetic inactivation; K ras; RASSF2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN; RASSF2A PROTEIN; UNCLASSIFIED DRUG; BISULFITE; PRIMER DNA; PROTEIN; RASSF2 PROTEIN, HUMAN; SULFITE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 20P; CODON; COLON ADENOMA; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA LIBRARY; DNA METHYLATION; FISHER EXACT TEST; GENE MUTATION; GENE STRUCTURE; HUMAN; HUMAN TISSUE; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BRAIN; CANCER STAGING; COLON TUMOR; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETICS; MALE; MOLECULAR CLONING; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BASE SEQUENCE; BRAIN; CELL LINE, TUMOR; CLONING, MOLECULAR; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; MALE; MUTATION; NEOPLASM STAGING; PROMOTER REGIONS (GENETICS); PROTEINS; SULFITES;

EID: 20544445183     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1208566     Document Type: Article

References (30)

1. Agathanggelou A, Bieche I, Aluned-Choudhury J, Nicke B, Dammann R, Baksh S, Gao BN, Minna JD, Downward J, Maher ER and Latif F. (2003). Cancer Res., 63, 5344-5351.
2. Agathanggelou A, Cooper WN and Latif F. (2005). Cancer Res. (in press).
3. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Radar J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F. (2001). Oncogene, 20, 1509-1518.
4. Behn M, Qun S, Pankow W, Havemann K and Schuermann M. (1998). Clin. Cancer Res., 4, 361-371.
5. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao BN, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD. (2001). J. Nat. Cancer Instit. 93, 691-699.
6. Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD, Clark GJ, Downward J, Maher ER and Latif F. (2004). Cancer Res., 64, 4112-4116.
7. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP. (2000). Nat. Genet., 25, 315-319.
8. Downward J. (2003). Nat. Rev. Cancer, 3, 11-22.
9. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li JF, Kashuba V, Klein G and Zabarovsky ER. (2001). Proc. Nat. Acad. Sci. USA, 98, 7504-7509.
10. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F and Clark GJ. (2004). Cancer Res., 64, 8688-8693.
11. Fearon ER and Vogelstein B. (1990). Cell, 61, 759-767.
12. Herman JG. (2002). Gastroenterol. Clin. North Am., 31, 945-958.
13. Hessen L, Bieche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER and Latif F. (2004). Oncogene, 23, 2408-2419.
14. Hessen L, Dallol A, Minna JD, Maher ER and Latif F. (2003). Oncogene, 22, 947-954.
15. Irimia M, Fraga MF, Sanchez-Cespedes M and Esteller M. (2004). Oncogene, 23, 8695-8699.
16. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B and Avruch J. (2002). Curr. Biol., 12, 253-265.
17. Kondo Y and Issa JP. (2004). Cancer Metast. Rev., 23, 29-39.
18. Lerman MI and Minna JD. (2000). Cancer Res., 60, 6116-6133.
19. Liu LM, Tommasi S, Lee DH, Dammann R and Pfeifer GP. (2003). Oncogene, 22, 8125-8136.
20. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, Muhlthaler M, Ofner D, Margreiter R and Widschwendter M. (2004). Lancet, 363, 1283-1285.
21. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP and Avruch J. (2002). Oncogene 21, 1381-1390.
22. Praskova M, Khoklatchev A, Ortiz-Vega S and Avruch J. (2004). Biochem. J., 381, 453-462.
23. Shivakumar L, Minna J, Sakamaki T, Pesteil R and White MA. (2002). Mol. Cell. Biol., 22, 4309-4318.
24. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG and Baylin SB. (2002). Nat. Genet., 31, 141-149.
25. Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J and Pfeifer GP. (2002). Oncogene, 21, 2713-2720.
26. van Engeland M, Roemen G, Brink M, Paachen MMM, Weijenberg MP, de Bruine AP, Arends JW, van den Brandt PA, de Goeij A and Herman JG. (2002). Oncogene, 21, 3792-3795.
27. Vavvas D, Li X, Avruch J and Zhang XF. (1998). J. Biol. Chem., 273, 5439-5442.
28. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ and Clark GJ. (2003). J. Biol. Chem., 278, 28045-28051.
29. Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F and Clark GJ. (2004). Cancer Res., 64, 4244-4250.
30. Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton D, Schofield PN, Reik W, Latif F and Maher ER. (2002). Oncogene, 21, 7277-7282.